Darolutamide plus standard hormone therapy for high-risk prostate cancer
Treatments studied
Part of Cancer, Kidney & urinary clinical trials.
This trial studies how safe darolutamide is and how well it works when added to standard hormone therapy for men with high-risk, non-metastatic prostate cancer that is no longer responding to hormone treatment. It may help slow prostate cancer growth and reduce prostate-specific antigen (PSA) rises in real-world care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You can sign informed consent and are a man age 18 or older.
- You have confirmed prostate cancer that is not a rare neuroendocrine/small-cell type.
- Your cancer has become resistant to standard hormone therapy: while on continuous ADT you’ve had at least 3 rising PSA tests over time, and your PSA at screening is at least 1.0 ng/mL.
- Your testosterone is in the “castrate” range (a specific lab number showing hormone suppression) while on treatment or after both testicles are removed.
- Your PSA is doubling “fast enough” to meet the trial rule (PSA doubling time of 10 months or less).
- You can join routine trial visits and take the study pills as required, and you do not need to skip due to swallowing problems or inability to follow the schedule.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study watches how well a drug called darolutamide works when combined with hormone therapy for men with prostate cancer that has returned after previous treatment. The goal is to understand if this combination helps prevent cancer spread and is safe to use.
This study tracks the safety of the drug darolutamide in Korean men with a type of prostate cancer that has not spread (non-metastatic) or has spread (metastatic) and is still responding to hormone therapy. It aims to see how well patients tolerate the drug in real-world settings.
This trial tests a combination of darolutamide (a pill that blocks male hormones) and standard hormone therapy (ADT) for men with high-risk prostate cancer that has not spread beyond the pelvis, after their prostate has been removed. The goal is to see if this treatment can help prevent the cancer from coming back.
This trial tests the drug darolutamide for men whose prostate cancer has spread and is no longer controlled by standard hormone therapy. It may be an option if you've already had certain hormone treatments for at least 12 months but your cancer is still progressing.
This trial tests a medicine called darolutamide taken with hormone therapy (ADT) before surgery to remove the prostate. It is for men with a high-risk prostate cancer that has not spread to other parts of the body.
This Phase 3 trial tests whether adding darolutamide to standard hormone therapy and radiation works better than standard treatment alone for newly diagnosed prostate cancer that has spread to pelvic lymph nodes. If you qualify, you may receive darolutamide or a placebo alongside long-term hormone therapy and radiation.
Hear when a new Non-metastatic Castration-resistant Prostate Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.